FRANKLIN, Tenn. / Feb 21, 2025 / Business Wire / Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced that the Company will participate in three investor conferences in March.
On Tuesday, March 4, 2025, the Company will participate in the Raymond James 46th Annual Institutional Investors Conference, being held March 2-5, 2025, in Orlando, Florida. The Company’s presentation will begin at 8:05 a.m. Eastern Time/7:05 a.m. Central Time.
On Tuesday, March 11, 2025, the Company will participate in the Leerink Partners 2025 Global Healthcare Conference, being held March 10-12, 2025, in Miami, Florida. The Company’s presentation will begin at 2:20 p.m. Eastern Time/1:20 p.m. Central Time.
On Wednesday, March 12, 2025, the Company will participate in the Barclays 27th Annual Global Healthcare Conference, being held March 11-13, 2025, in Miami, Florida. The Company’s presentation will begin at 9:30 a.m. Eastern Time/8:30 a.m. Central Time.
The live webcast of all the presentations will be available on the Company’s website, www.acadiahealthcare.com, by clicking on the “Investors” link. A replay of the presentations will also be available on the Company’s website for 30 days.
About Acadia
Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2024, Acadia operated a network of 260 behavioral healthcare facilities with approximately 11,300 beds in 38 states and Puerto Rico. With approximately 23,500 employees serving more than 80,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.
Last Trade: | US$21.09 |
Daily Change: | -0.68 -3.12 |
Daily Volume: | 1,844,742 |
Market Cap: | US$1.940B |
May 12, 2025 February 27, 2025 October 30, 2024 July 31, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAstria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MOREEnd of content
No more pages to load